Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm Abstract #2703

Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Aim(s): Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs (SSAs) being the first-line option for symptom management.
Materials and methods: In this single-centre study, we retrospectively analysed the diagnostic process and outcome of all patients CHD who underwent sandostatin analogue 120 mg between 2016 and 2019 with or without chemotherapy. We report a series of 12 patients followed in the medical oncology departement we propose a new CHD manegement algorithm
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1041 Surgical Management of Carcinoid Valve Disease-Mechanical versus Tissue Valves
Introduction: The prosthetic valve of choice in patients with carcinoid valve disease (CVD) remains controversial due to the limited life expectancy of patients with advanced-stage neuroendocrine tumors (NETs) on one hand, and concerns regarding structural valve deterioration (SVD) on the other.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Simona Glasberg
Authors: Glasberg S, Atlan J, Korach A, Dabah A, ...
#1655 A Case Report of Bicaval Stents and Inferior Vena Cava Valve Implantation to Control Carcinoid Symptoms in Order to Safely Allow Surgical Valve Replacement
Introduction: Surgery for severe tricuspid regurgitation (TR) is a high-risk procedure. Therefore transcatheter valve implantation into the vena cava can be performed as an attempt to reduce the complications and symptoms associated with this.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Dr Vandana Sagar
Authors: Sagar V, Steeds R, Doshi S, Shetty S, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#2706 A New Possibility in SI-NET Surgery by Using a New β- Probe and 90Y-DOTATOC: A Pilot Study
Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Chiara Maria Grana